Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Lanreotide and Octreotide LAR for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Observational Time and Motion Analysis
Sponsor: Ipsen
Listed as NCT03017690, this observational or N/A phase trial focuses on Gastroenteropancreatic Neuroendocrine Tumor and remains completed. Sponsored by Ipsen, it has been updated 12 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jan 2019 — Jan 2021 [monthly]
Completed
-
Aug 2018 — Jan 2019 [monthly]
Completed
Status: Recruiting → Completed
▶ Show 7 earlier versions
-
Jul 2018 — Aug 2018 [monthly]
Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Sep 2017 — Apr 2018 [monthly]
Recruiting NA
-
Jul 2017 — Sep 2017 [monthly]
Recruiting NA
-
Mar 2017 — Jul 2017 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Mar 2017 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ipsen
For direct contact, visit the study record on ClinicalTrials.gov .